4.7 Article

Electroretinography as a Biomarker to Monitor the Progression of Stargardt Disease

Journal

Publisher

MDPI
DOI: 10.3390/ijms232416161

Keywords

Stargardt disease; ABCA4 gene; electroretinographic biomarkers; electroretinography; electrophysiology; retinal dystrophy; S-cone ERG; DA 0; 01 ERG b-wave; DA 3; 0 ERG a-wave

Funding

  1. Slovenian research agency
  2. [ARRS J3-1750]

Ask authors/readers for more resources

The aim of this study was to determine how electroretinographic (ERG) responses reflect age-related disease progression in Stargardt disease (STGD1). The study found that specific ERG responses can be used to detect double-null patients at an early stage and monitor disease progression in patients with specific genotypes.
The aim of the present study is to determine how electroretinographic (ERG) responses reflect age-related disease progression in the Stargardt disease (STGD1). The prospective comparative cohort study included 8 patients harboring two null ABCA4 variants (Group 1) and 34 patients with other ABCA4 genotypes (Group 2). Age at exam, age at onset, visual acuity (VA) and ERG responses were evaluated. The correlation between ERG responses and age in each patient group was determined using linear regression. A Mann-Whitney U Test was used to compare the median values between the groups. Age of onset was significantly earlier in Group 1 than in Group 2 (8 vs. 18), while disease duration was similar (13 vs. 12 years, i.e., advanced stage). Group 1 had significantly worse VA and lower ERG responses. ERG responses that significantly correlated with age in Group 1 were DA 0.01 and 3.0 ERG, which represented a retinal rod system response. The only ERG response that significantly correlated with age in Group 2 was the S-cone ERG. The observed difference was likely due to early cone loss occurring in double-null patients and slower photoreceptor loss in patients with other genotypes. The results suggest that specific ERG responses may be used to detect double-null patients at an early stage and monitor STGD1 disease progression in patients with specific genotypes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available